SCHEMBL2503099

SCHEMBL2503099

C[C@H](c1ccc(CO[Si](C)(C)C(C)(C)C)cc1Cl)c1ccccc1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRG P23470 1/20 0.36
USP14 P54578 1/20 0.35
KMT2A Q03164 5/20 0.34
MEN1 O00255 4/20 0.34
ALDH1A1 P00352 4/20 0.34
GAA P10253 2/20 0.34
ABL1 P00519 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
RIN1 Q13671 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
APEX1 P27695 1/20 0.34
FFAR1 O14842 1/20 0.34
MRGPRX4 Q96LA9 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
NR1H4 Q96RI1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2503098 1.00 PTPRG (0.36) PTPRGUSP14KMT2AMEN1ALDH1A1
SCHEMBL2501481 0.79 PDE2A (0.43) USP14KMT2AMEN1LMNAFFAR1
SCHEMBL2499335 0.79 PDE2A (0.43) USP14KMT2AMEN1LMNAFFAR1
SCHEMBL2504808 0.79 PTPRG (0.43) PTPRGKMT2AMEN1ALDH1A1GAA
SCHEMBL2504810 0.79 PTPRG (0.43) PTPRGKMT2AMEN1ALDH1A1GAA
SCHEMBL2853361 0.74 ALDH1A1 (0.38) USP14ALDH1A1LMNAMRGPRX4TDP1
SCHEMBL20556155 0.74 ALDH1A1 (0.37) KMT2AMEN1ALDH1A1GAAMAPT
SCHEMBL29288338 0.72 NR1H4 (0.47) USP14RAB9AMRGPRX4NR1H4
SCHEMBL30740752 0.72 RAB9A (0.44) KMT2AMEN1ALDH1A1LMNARAB9A
SCHEMBL4801879 0.72 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 PTPRG 4508/4885USP14 2983/4885KMT2A 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.